A phase I and pharmacologic study of idarubicin, cytarabine, etoposide, and the multidrug resistance protein (MDR1/Pgp) inhibitor PSC-833 in patients with refractory leukemia
- 31 March 2005
- journal article
- clinical trial
- Published by Elsevier in Leukemia Research
- Vol. 29 (3), 263-271
- https://doi.org/10.1016/j.leukres.2004.07.002
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720Blood, 2002
- Fludarabine, Arabinosyl Cytosine and Idarubicin (FLAI) for Remission Induction in Poor-Risk Acute Myeloid LeukemiaLeukemia & Lymphoma, 2001
- Cytosine Arabinoside, Idarubicin and Divided Dose Etoposide for the Treatment of Acute Myeloid Leukemia in Elderly PatientsLeukemia & Lymphoma, 2001
- Has the prognosis of adult patients with acute myeloid leukemia improved over years? A single institution experience of 784 consecutive patients over a 16-year periodLeukemia, 1999
- Parallel Phase I Studies of Daunorubicin Given With Cytarabine and Etoposide With or Without the Multidrug Resistance Modulator PSC-833 in Previously Untreated Patients 60 Years of Age or Older With Acute Myeloid Leukemia: Results of Cancer and Leukemia Group B Study 9420Journal of Clinical Oncology, 1999
- Susceptibility of idarubicin, daunorubicin, and their C-13 alcohol metabolites to transport-mediated multidrug resistanceBiochemical Pharmacology, 1995
- Intensive Postremission Chemotherapy in Adults with Acute Myeloid LeukemiaNew England Journal of Medicine, 1994
- Clinical Pharmacokinetics of IdarubicinClinical Pharmacokinetics, 1993
- Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia.Journal of Clinical Oncology, 1990
- A program package for simulation and parameter estimation in pharmacokinetic systemsComputer Programs in Biomedicine, 1979